Clarus Wealth Advisors’s Biogen BIIB Stock Holding History

Clarus Wealth Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-2,540	Closed	-$681K	–	104
2021 Q1	$681K	Hold	2,540	–	–	0.43%	48
2020 Q4	$680K	Hold	2,540	–	–	0.45%	45
2020 Q3	$714K	Hold	2,540	–	–	0.55%	38
2020 Q2	$682K	Hold	2,540	–	–	0.57%	38
2020 Q1	$763K	Hold	2,540	–	–	0.76%	30
2019 Q4	$748K	Hold	2,540	–	–	0.49%	57
2019 Q3	$591K	Buy	+2,540	New	+$591K	0.43%	51

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Clarus Wealth Advisors's BIIB Position: Q2 2021 in Review

Clarus Wealth Advisors sold out of Biogen (BIIB) in Q2 2021, closing a stake of 2,540 shares — an estimated $681K sold.

Clarus Wealth Advisors first reported a position in BIIB in Q3 2019 and held it in 7 quarters. The position peaked at $763K in Q1 2020. 1,106 funds tracked by Wall St. Rank hold BIIB as of Q2 2021.

Clarus Wealth Advisors reported no remaining Biogen position as of Q2 2021 after selling out during the quarter.
Clarus Wealth Advisors sold 2,540 Biogen shares in Q2 2021, an estimated $681K.
Clarus Wealth Advisors first reported a position in Biogen in Q3 2019 and held it in 7 quarters.
Clarus Wealth Advisors's Biogen position peaked at $763K in Q1 2020.
1,106 funds tracked by Wall St. Rank held Biogen as of Q2 2021.

Based on Clarus Wealth Advisors's 13F filing for Q2 2021, filed 13 Jul 2021.